• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
De-Escalation Strategies in HPV-Associated Oropharynx Cancer-Are we Putting the Cart Before the Horse?人乳头瘤病毒相关口咽癌的降阶梯治疗策略——我们是否本末倒置了？
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):705-709. doi: 10.1016/j.ijrobp.2019.02.054.
2
HPV-associated oropharyngeal cancer de-escalation strategies and trials: Past failures and future promise.HPV 相关口咽癌降阶治疗策略及临床试验：既往失败与未来前景。
J Surg Oncol. 2021 Nov;124(6):962-966. doi: 10.1002/jso.26696. Epub 2021 Sep 30.
3
Cetuximab in Human Papillomavirus-Positive Oropharynx Carcinoma.西妥昔单抗用于人乳头瘤病毒阳性口咽癌的治疗
J Clin Oncol. 2016 Apr 20;34(12):1289-91. doi: 10.1200/JCO.2015.65.1414. Epub 2016 Feb 16.
4
Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?针锋相对：我们现在是否应降低人乳头瘤病毒相关口咽癌的治疗强度？以及如何降低？
Am Soc Clin Oncol Educ Book. 2019 Jan;39:364-372. doi: 10.1200/EDBK_238315. Epub 2019 May 17.
5
Radiation Dose De-Escalation in HPV-Positive Oropharynx Cancer: When Will It Be an Acceptable Standard of Care?人乳头瘤病毒阳性口咽癌的放射剂量递减：何时会成为可接受的护理标准？
J Clin Oncol. 2021 Mar 20;39(9):947-949. doi: 10.1200/JCO.21.00017. Epub 2021 Feb 12.
6
Human papillomavirus-related oropharyngeal cancer.人乳头瘤病毒相关性口咽癌。
Ann Oncol. 2017 Oct 1;28(10):2386-2398. doi: 10.1093/annonc/mdx304.
7
[In HPV-associated oropharyngeal cancer, chemoradiotherapy with cisplatin is superior to bioradiotherapy with cetuximab in terms of overall survival].在人乳头瘤病毒相关的口咽癌中，就总生存期而言，顺铂同步放化疗优于西妥昔单抗生物放疗。
Strahlenther Onkol. 2019 May;195(5):447-449. doi: 10.1007/s00066-019-01441-w.
8
HPV-related oropharyngeal carcinoma de-escalation protocols.人乳头瘤病毒相关口咽癌的降阶梯治疗方案。
Lancet Oncol. 2017 Jun;18(6):704-705. doi: 10.1016/S1470-2045(17)30250-4. Epub 2017 Apr 20.
9
Update on De-intensification and Intensification Studies in HPV.人乳头瘤病毒减量化与强化研究的最新进展
Recent Results Cancer Res. 2017;206:251-256. doi: 10.1007/978-3-319-43580-0_20.
10
[Aggressive dose de-escalation in adjuvant therapy for HPV-associated oropharyngeal cancer. Is half of everything enough?].[人乳头瘤病毒相关口咽癌辅助治疗中积极的剂量降阶梯。一切减半就足够了吗？]
Strahlenther Onkol. 2020 May;196(5):492-494. doi: 10.1007/s00066-020-01602-2.

引用本文的文献

1
Cancer cell - Fibroblast crosstalk via HB-EGF, EGFR, and MAPK signaling promotes the expression of macrophage chemo-attractants in squamous cell carcinoma.癌细胞与成纤维细胞通过肝素结合表皮生长因子（HB-EGF）、表皮生长因子受体（EGFR）和丝裂原活化蛋白激酶（MAPK）信号通路的相互作用促进了巨噬细胞趋化因子在鳞状细胞癌中的表达。
iScience. 2024 Aug 3;27(9):110635. doi: 10.1016/j.isci.2024.110635. eCollection 2024 Sep 20.
2
Personalized precision radiotherapy and its evolving role for human papillomavirus-positive oropharyngeal cancer.个性化精准放疗及其在人乳头瘤病毒阳性口咽癌中不断演变的作用。
J Natl Cancer Cent. 2022 Dec 30;3(1):72-82. doi: 10.1016/j.jncc.2022.11.006. eCollection 2023 Mar.
3
GA-OH enhances the cytotoxicity of photon and proton radiation in HPV HNSCC cells.GA-OH增强了人乳头瘤病毒相关头颈部鳞状细胞癌（HPV HNSCC）细胞对光子和质子辐射的细胞毒性。
Front Oncol. 2023 Feb 10;13:1070485. doi: 10.3389/fonc.2023.1070485. eCollection 2023.
4
p53 Modulates Radiosensitivity in Head and Neck Cancers-From Classic to Future Horizons.p53调节头颈癌的放射敏感性——从经典到未来展望
Diagnostics (Basel). 2022 Dec 5;12(12):3052. doi: 10.3390/diagnostics12123052.
5
Novel Strategies for Managing Retropharyngeal Lymph Node Metastases in Head and Neck and Thyroid Cancer with Transoral Robotic Surgery (TORS).经口机器人手术（TORS）治疗头颈部和甲状腺癌咽后淋巴结转移的新策略。
Ann Surg Oncol. 2022 Nov;29(12):7881-7890. doi: 10.1245/s10434-022-12208-6. Epub 2022 Jul 16.
6
The accuracy of clinical neck staging for p16-positive and negative oropharyngeal cancer and its therapeutic implications.p16 阳性和阴性口咽癌的临床颈部分期准确性及其治疗意义。
Eur Arch Otorhinolaryngol. 2022 Nov;279(11):5339-5345. doi: 10.1007/s00405-022-07430-7. Epub 2022 Jul 4.
7
Micro-RNAs, the Cornerstones of the Future of Radiobiology in Head and Neck Cancers?微小 RNA ：头颈部癌症放射生物学未来的基石？
Curr Oncol. 2022 Feb 2;29(2):816-833. doi: 10.3390/curroncol29020069.
8
Radiomics Predicts for Distant Metastasis in Locally Advanced Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma.放射组学预测局部晚期人乳头瘤病毒阳性口咽鳞状细胞癌的远处转移
Cancers (Basel). 2021 Nov 14;13(22):5689. doi: 10.3390/cancers13225689.
9
Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirations.放射治疗生物库：现状、机遇、挑战和未来展望。
J Pathol Clin Res. 2022 Jan;8(1):3-13. doi: 10.1002/cjp2.246. Epub 2021 Oct 17.
10
Targeted Therapy as a Potential De-Escalation Strategy in Locally Advanced HPV-Associated Oropharyngeal Cancer: A Literature Review.靶向治疗作为局部晚期人乳头瘤病毒相关口咽癌潜在的降阶梯治疗策略：文献综述
Front Oncol. 2021 Aug 17;11:730412. doi: 10.3389/fonc.2021.730412. eCollection 2021.

本文引用的文献

1
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.放疗联合西妥昔单抗或顺铂治疗人乳头瘤病毒阳性口咽癌（NRG 肿瘤学 RTOG 1016）：一项随机、多中心、非劣效性试验。
Lancet. 2019 Jan 5;393(10166):40-50. doi: 10.1016/S0140-6736(18)32779-X. Epub 2018 Nov 15.
2
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.放疗联合顺铂或西妥昔单抗治疗低危型人乳头瘤病毒阳性口咽癌（De-ESCALaTE HPV）：一项开放标签随机对照 3 期临床试验。
Lancet. 2019 Jan 5;393(10166):51-60. doi: 10.1016/S0140-6736(18)32752-1. Epub 2018 Nov 15.
3
Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.低危型人乳头瘤病毒相关口咽鳞状细胞癌去强化放化疗的前瞻性研究的成熟结果。
Cancer. 2018 Jun 1;124(11):2347-2354. doi: 10.1002/cncr.31338. Epub 2018 Mar 26.
4
Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.低剂量放疗治疗人乳头瘤病毒相关口咽鳞癌的单臂、2 期研究。
Lancet Oncol. 2017 Jun;18(6):803-811. doi: 10.1016/S1470-2045(17)30246-2. Epub 2017 Apr 20.
5
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.E1308：诱导化疗后降低剂量放疗联合西妥昔单抗每周治疗人乳头瘤病毒相关可切除口咽鳞状细胞癌患者的II期试验 - ECOG-ACRIN癌症研究组
J Clin Oncol. 2017 Feb 10;35(5):490-497. doi: 10.1200/JCO.2016.68.3300. Epub 2016 Dec 28.
6
Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial.顺铂同步标准放疗与帕尼单抗同步加速放疗治疗局部晚期头颈部鳞状细胞癌的疗效：一项随机临床试验
JAMA Oncol. 2017 Feb 1;3(2):220-226. doi: 10.1001/jamaoncol.2016.4510.
7
Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis.头颈部鳞状细胞癌放疗联合顺铂与西妥昔单抗对比的生存、复发及毒性：一项荟萃分析
BMC Cancer. 2016 Aug 26;16(1):689. doi: 10.1186/s12885-016-2706-2.
8
Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study.国际口咽癌协作网（ICON-S）制定和验证 HPV 相关口咽癌分期系统：一项多中心队列研究。
Lancet Oncol. 2016 Apr;17(4):440-451. doi: 10.1016/S1470-2045(15)00560-4. Epub 2016 Feb 27.
9
Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial.西妥昔单抗联合放疗对比顺铂联合放疗治疗局部晚期头颈部鳞癌：一项随机 II 期试验。
J Clin Oncol. 2016 Feb 10;34(5):427-35. doi: 10.1200/JCO.2015.63.1671. Epub 2015 Dec 7.
10
Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors.人乳头瘤病毒相关头颈部癌的基因图谱及其与烟草相关肿瘤的比较。
J Clin Oncol. 2015 Oct 10;33(29):3227-34. doi: 10.1200/JCO.2015.62.1086. Epub 2015 Sep 8.

De-Escalation Strategies in HPV-Associated Oropharynx Cancer-Are we Putting the Cart Before the Horse?

作者信息

Anderson Carryn M, Kimple Randall J, Lin Alexander, Karam Sana D, Margalit Danielle N, Chua Melvin L K

出版信息

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):705-709. doi: 10.1016/j.ijrobp.2019.02.054.

DOI:10.1016/j.ijrobp.2019.02.054
PMID:31204653
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7194352/
Abstract
摘要